Cabot Corporation
NYSE:CBTChemicals - Specialty
+$0.96 today
- Market cap
- $3.80B
- Beta
- 0.83
- P/E (TTM)
- 16.3
- EPS (TTM)
- $5.48
- Dividend yield
- 2.04%
Volume 0.53M
Average 0.43M
CBT Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Cabot CorporationNYSE: CBT
Other Income / Expenses · Q3 FY2026 · quarter ended Jun 2026
Other income / expenses remains negative
Q3 FY2026 other income / expenses was -$38M, compared with -$11M a year earlier. Trailing-twelve-month other income / expenses was -$83M.
Context
- Other income / expenses amounted to 1.3% of revenue in FY2025, down 0.7 pp from a year earlier.
- Other income / expenses grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly other income / expenses holds near -$38M or moves back toward the trailing-twelve-month quarterly average of -$20.75M.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- (49M) USD
- Year-over-year change
- +38.0%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | (49M) | +38.0% |
| FY2024 | 2024-09-30 | (79M) | -12.9% |
| FY2023 | 2023-09-30 | (70M) | -59.1% |
| FY2022 | 2022-09-30 | (44M) | +2.2% |
| FY2021 | 2021-09-30 | (45M) | — |
Other Income / Expenses vs competitors
How CBT compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -93.0% is the 9th highest of 11, against a peer median of -9.9%.
- Other income / expenses amounts to 2.3% of revenue for CBT, versus a peer median of 3.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | -$2.44M USD | -12.5% | — | 0.4% | |
| LTM Sep 2026 | -$5.11M USD | +36.2% | — | 0.4% | |
| LTM Jun 2026 | -$30.93M USD | -7.3% | — | 1.8% | |
| LTM Jun 2026 | -$83M USD | -93.0% | — | 2.3% | |
| LTM Jun 2026 | -$86.38M USD | -62.5% | — | 2.6% | |
| LTM Sep 2026 | -$88.8M USD | +15.0% | — | 2.6% | |
| LTM Aug 2026 | -$142.29M USD | +18.1% | — | 4.0% | |
| LTM Jun 2026 | -$215.74M USD | -281.1% | — | 28.5% | |
| LTM Jun 2026 | -$437.71M USD | -358.5% | — | 10.3% | |
| LTM Jun 2026 | -$441M USD | +1.6% | — | 4.5% | |
| FY2026 | -ZAR 37.55B ZAR | -43.4% | — | 14.1% | |
| Peer median (excluding CBT) | — | -9.9% | — | 3.3% | |
Competitors are the stored peer set for CBT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 3.41B | 4.32B | 3.93B | 3.99B | 3.71B |
| Cost of Revenue | 2.61B | 3.44B | 3.09B | 3.03B | 2.77B |
| Gross Profit | 799M | 885M | 839M | 960M | 940M |
| Gross Margin | 23.4% | 20.5% | 21.3% | 24.0% | 25.3% |
| Research & Development | 56M | 55M | 57M | 63M | 59M |
| Selling, General & Admin | 289M | 258M | 253M | 283M | 260M |
| Operating Expenses | 345M | 496M | 313M | 346M | 319M |
| Depreciation & Amortization | 160M | 146M | 144M | 151M | 154M |
| EBITDA | 615M | 537M | 685M | 761M | 794M |
| EBITDA Margin | 18.0% | 12.4% | 17.4% | 19.1% | 21.4% |
| Operating Income | 454M | 389M | 526M | 614M | 621M |
| Operating Margin | 13.3% | 9.0% | 13.4% | 15.4% | 16.7% |
| Interest Income | 8M | 11M | 31M | 32M | 27M |
| Interest Expense | 49M | 56M | 90M | 81M | 76M |
| Other Income / Expenses | (45M) | (44M) | (70M) | (79M) | (49M) |
| Income Before Tax | 409M | 345M | 456M | 535M | 572M |
| Pre-Tax Margin | 12.0% | 8.0% | 11.6% | 13.4% | 15.4% |
| Income Tax Expense | 123M | 102M | (28M) | 111M | 196M |
| Net Income | 250M | 209M | 445M | 380M | 331M |
| Net Margin | 7.3% | 4.8% | 11.3% | 9.5% | 8.9% |
| EPS (Basic) | 4.36 | 3.65 | 7.79 | 6.79 | 6.07 |
| EPS (Diluted) | 4.34 | 3.62 | 7.73 | 6.72 | 6.02 |
| Weighted Avg Shares | 56.73M | 56.25M | 55.24M | 54.3M | 53.7M |
| Weighted Avg Shares (Diluted) | 56.8M | 56.9M | 56.5M | 55.7M | 54.2M |
Cabot Corporation
NYSE:CBT
Intrinsic Alpha fair value
Locked
Current Price
$74.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.